QQQ   357.33 (+0.76%)
AAPL   184.45 (+1.93%)
MSFT   338.25 (+0.85%)
META   274.12 (+0.55%)
GOOGL   126.99 (+1.86%)
AMZN   125.19 (+0.76%)
TSLA   219.14 (+2.42%)
NVDA   391.95 (-0.34%)
NIO   7.79 (+3.04%)
BABA   84.02 (-0.30%)
AMD   118.73 (+0.74%)
T   15.34 (+0.85%)
F   12.67 (+2.26%)
MU   68.14 (-1.49%)
CGC   0.79 (-4.57%)
GE   104.83 (-0.92%)
DIS   90.37 (-0.44%)
AMC   4.62 (+1.54%)
PFE   38.79 (+1.12%)
PYPL   64.94 (+1.53%)
NFLX   412.96 (+3.12%)
QQQ   357.33 (+0.76%)
AAPL   184.45 (+1.93%)
MSFT   338.25 (+0.85%)
META   274.12 (+0.55%)
GOOGL   126.99 (+1.86%)
AMZN   125.19 (+0.76%)
TSLA   219.14 (+2.42%)
NVDA   391.95 (-0.34%)
NIO   7.79 (+3.04%)
BABA   84.02 (-0.30%)
AMD   118.73 (+0.74%)
T   15.34 (+0.85%)
F   12.67 (+2.26%)
MU   68.14 (-1.49%)
CGC   0.79 (-4.57%)
GE   104.83 (-0.92%)
DIS   90.37 (-0.44%)
AMC   4.62 (+1.54%)
PFE   38.79 (+1.12%)
PYPL   64.94 (+1.53%)
NFLX   412.96 (+3.12%)
QQQ   357.33 (+0.76%)
AAPL   184.45 (+1.93%)
MSFT   338.25 (+0.85%)
META   274.12 (+0.55%)
GOOGL   126.99 (+1.86%)
AMZN   125.19 (+0.76%)
TSLA   219.14 (+2.42%)
NVDA   391.95 (-0.34%)
NIO   7.79 (+3.04%)
BABA   84.02 (-0.30%)
AMD   118.73 (+0.74%)
T   15.34 (+0.85%)
F   12.67 (+2.26%)
MU   68.14 (-1.49%)
CGC   0.79 (-4.57%)
GE   104.83 (-0.92%)
DIS   90.37 (-0.44%)
AMC   4.62 (+1.54%)
PFE   38.79 (+1.12%)
PYPL   64.94 (+1.53%)
NFLX   412.96 (+3.12%)
QQQ   357.33 (+0.76%)
AAPL   184.45 (+1.93%)
MSFT   338.25 (+0.85%)
META   274.12 (+0.55%)
GOOGL   126.99 (+1.86%)
AMZN   125.19 (+0.76%)
TSLA   219.14 (+2.42%)
NVDA   391.95 (-0.34%)
NIO   7.79 (+3.04%)
BABA   84.02 (-0.30%)
AMD   118.73 (+0.74%)
T   15.34 (+0.85%)
F   12.67 (+2.26%)
MU   68.14 (-1.49%)
CGC   0.79 (-4.57%)
GE   104.83 (-0.92%)
DIS   90.37 (-0.44%)
AMC   4.62 (+1.54%)
PFE   38.79 (+1.12%)
PYPL   64.94 (+1.53%)
NFLX   412.96 (+3.12%)
NASDAQ:ZLAB

Zai Lab (ZLAB) Stock Forecast, Price & News

$35.14
-0.56 (-1.57%)
(As of 12:58 PM ET)
Compare
Today's Range
$33.50
$35.80
50-Day Range
$30.78
$39.67
52-Week Range
$20.98
$53.95
Volume
158,827 shs
Average Volume
685,035 shs
Market Capitalization
$3.44 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$94.33

Zai Lab MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
174.1% Upside
$94.33 Price Target
Short Interest
Healthy
3.34% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.75mentions of Zai Lab in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$322,981 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.08) to ($2.20) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

296th out of 980 stocks

Pharmaceutical Preparations Industry

136th out of 485 stocks


ZLAB stock logo

About Zai Lab (NASDAQ:ZLAB) Stock

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.

Receive ZLAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter.

ZLAB Stock News Headlines

Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium
The soaring demand for lithium is driven by worldwide demand for electric vehicles (EVs). Lithium is ideal for electric cars. It's lightweight, stores lots of energy and is rechargeable. Sales of EVs are expected to increase 10-fold by 2030 and estimates are that 1 in 2 cars sold will be electric by 2040.
Zai Lab (NASDAQ:ZLAB) Shares Down 5.4%
Zai Lab (ZLAB): New Buy Recommendation for This Technology Giant
12 Best Chinese Stocks to Buy Now
Zai Lab (NASDAQ:ZLAB) Shares Gap Up to $31.50
Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium
The soaring demand for lithium is driven by worldwide demand for electric vehicles (EVs). Lithium is ideal for electric cars. It's lightweight, stores lots of energy and is rechargeable. Sales of EVs are expected to increase 10-fold by 2030 and estimates are that 1 in 2 cars sold will be electric by 2040.
Zai Lab (NASDAQ: ZLAB)
Citigroup Cuts Zai Lab (NASDAQ:ZLAB) Price Target to $130.00
Zai Lab: Q1 Earnings Insights
Earnings Preview For Zai Lab
See More Headlines

ZLAB Price History

ZLAB Company Calendar

Last Earnings
5/09/2023
Today
6/05/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ZLAB
Employees
2,036
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$94.33
High Stock Price Forecast
$130.00
Low Stock Price Forecast
$70.00
Forecasted Upside/Downside
+173.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-443,290,000.00
Net Margins
-177.42%
Pretax Margin
-177.42%

Debt

Sales & Book Value

Annual Sales
$215.04 million
Book Value
$10.68 per share

Miscellaneous

Free Float
92,788,000
Market Cap
$3.38 billion
Optionable
Optionable
Beta
1.15

Key Executives

  • Ying DuYing Du
    Chairman & Chief Executive Officer
  • Rafael G. Amado
    President
  • Joshua L. Smiley
    Chief Operating Officer
  • Billy Cho
    Chief Financial Officer
  • Ning Xu
    Executive VP & Head-Clinical Operations













ZLAB Stock - Frequently Asked Questions

Should I buy or sell Zai Lab stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZLAB shares.
View ZLAB analyst ratings
or view top-rated stocks.

What is Zai Lab's stock price forecast for 2023?

2 brokerages have issued twelve-month target prices for Zai Lab's shares. Their ZLAB share price forecasts range from $70.00 to $130.00. On average, they anticipate the company's stock price to reach $94.33 in the next year. This suggests a possible upside of 164.2% from the stock's current price.
View analysts price targets for ZLAB
or view top-rated stocks among Wall Street analysts.

How have ZLAB shares performed in 2023?

Zai Lab's stock was trading at $30.70 on January 1st, 2023. Since then, ZLAB stock has increased by 16.3% and is now trading at $35.70.
View the best growth stocks for 2023 here
.

When is Zai Lab's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our ZLAB earnings forecast
.

How were Zai Lab's earnings last quarter?

Zai Lab Limited (NASDAQ:ZLAB) posted its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.51) earnings per share for the quarter, beating analysts' consensus estimates of ($0.94) by $0.43. The business had revenue of $62.80 million for the quarter, compared to the consensus estimate of $65.21 million. Zai Lab had a negative trailing twelve-month return on equity of 37.58% and a negative net margin of 177.42%.

What other stocks do shareholders of Zai Lab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).

When did Zai Lab IPO?

(ZLAB) raised $100 million in an initial public offering on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO.

What is Zai Lab's stock symbol?

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

Who are Zai Lab's major shareholders?

Zai Lab's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.48%), FMR LLC (3.14%), Price T Rowe Associates Inc. MD (2.46%), Segantii Capital Management Ltd (2.33%), Credit Suisse AG (2.25%) and Genesis Investment Management LLP (1.60%). Insiders that own company stock include Frazor Titus Edmondson III, Harald Reinhart, John D Diekman, John D Diekman, Kai-Xian Chen, Peter Wirth, Tao Fu, William Ki Chul Cho, William Lis and Ying Du.
View institutional ownership trends
.

How do I buy shares of Zai Lab?

Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zai Lab's stock price today?

One share of ZLAB stock can currently be purchased for approximately $35.70.

How much money does Zai Lab make?

Zai Lab (NASDAQ:ZLAB) has a market capitalization of $3.50 billion and generates $215.04 million in revenue each year. The company earns $-443,290,000.00 in net income (profit) each year or ($4.28) on an earnings per share basis.

How many employees does Zai Lab have?

The company employs 2,036 workers across the globe.

How can I contact Zai Lab?

Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The official website for the company is www.zailaboratory.com. The company can be reached via phone at 862161632588, via email at jsteier@burnsmc.com, or via fax at 86-21-6163-2570.

This page (NASDAQ:ZLAB) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -